EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mefloquine Suppresses Metastasis in Renal Cell Carcinoma Through Targeting SPC25

Yongbo Wang iD, He Wang, Yipeng Xu, Jiawei Ling, Chuhong Zong, Yan Zhang, Xiaoxuan Guo, Guanan Zhao, Yuan Zhou, Jiahui Zhao, Pengrong Lou, Xigao Liu und 2 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yongbo Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cixi Biomedical Research Institute, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Mefloquine. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical and Health Research Project of Zhejiang Province, Natural Science Foundation of Zhejiang Province, the Public Welfare Technology Application Research Project of Lishui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) is the third most common malignant tumor in the urinary system, often presenting with distant metastases at diagnosis. Approximately one‐quarter of patients undergoing nephrectomy experience distant recurrence. Despite the recent advancements in combination‐targeted and immune checkpoint inhibitor therapies, the development of new therapeutic strategies and the identification of biomarkers for metastatic risk remain crucial. The study found that high SPC25 expression is closely associated with poor clinical outcomes, and knocking down SPC25 significantly inhibits tumor cell proliferation and migration. Non‐targeted metabolomics analysis also revealed that SPC25 knockdown reduces tumor cell activity, resulting in a low‐invasive state. Additionally, this study utilized high‐throughput molecular docking to screen small molecule drugs targeting SPC25, aiming to find drugs that inhibit RCC metastasis. The research discovered that mefloquine, at concentrations that do not significantly kill tumor cells, can markedly inhibit RCC metastasis. It was the first to report that mefloquine achieves its anti‐metastatic effects by binding to SPC25 and inhibiting epithelial‐mesenchymal transition. These results suggest that SPC25 has the potential to serve as an early biomarker for metastatic risk in RCC and highlight a novel strategy where mefloquine inhibits RCC metastasis through SPC25 binding, offering new avenues to improve the prognosis of RCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsMefloquineHumansEpithelial-Mesenchymal TransitionCell Line, TumorCell ProliferationCell MovementMolecular Docking SimulationBiomarkers, TumorPrognosisMaleAnimalsFemaleNeoplasm MetastasisMice

Stichwörter der Autor:innen

SPC25mefloquinerenal cell carcinomatumor migration

Substanzen

MefloquineBiomarkers, Tumor

Autor:innen und Institutionen

  • Cixi Biomedical Research Institute, Wenzhou Medical University, Wenzhou, China.
  • The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of Urology, Zhejiang Cancer Hospital, Hangzhou, China.
  • The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China.
  • State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Postgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Yongbo Wang, Qi Ma

Förderung

  • Medical and Health Research Project of Zhejiang Province
  • Natural Science Foundation of Zhejiang Province
  • the Public Welfare Technology Application Research Project of Lishui

Zitieren

APA

Wang, Y., Wang, H., Xu, Y., Ling, J., Zong, C., Zhang, Y., Guo, X., Zhao, G., Zhou, Y., Zhao, J., Lou, P., Liu, X., Xu, T., & Ma, Q. (2025). Mefloquine Suppresses Metastasis in Renal Cell Carcinoma Through Targeting SPC25. Cancer Science. https://doi.org/10.1111/cas.70001

Vancouver

Wang Y, Wang H, Xu Y, Ling J, Zong C, Zhang Y, et al. Mefloquine Suppresses Metastasis in Renal Cell Carcinoma Through Targeting SPC25. Cancer Science. 2025. doi:10.1111/cas.70001

BibTeX
@article{Wang2025,
  author = {Wang, Yongbo and Wang, He and Xu, Yipeng and Ling, Jiawei and Zong, Chuhong and Zhang, Yan and Guo, Xiaoxuan and Zhao, Guanan and Zhou, Yuan and Zhao, Jiahui and Lou, Pengrong and Liu, Xigao and Xu, Tengfei and Ma, Qi},
  title = {Mefloquine Suppresses Metastasis in Renal Cell Carcinoma Through Targeting SPC25},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70001}
}
Kostenlos starten →